1 completed, 1 withdrawn. 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1 | Withdrawn 1 |
Follow Diamant Thaci: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet - Moderate to Severe Plaque Psoriasis | Phase 4 | Withdrawn | Diamant Thaci | 2017-10-23 | 2019-04-18 | |
| Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients Secukinumab - Psoriasis Vulgaris | Completed | Diamant Thaci | 40 | 2016-10-01 | 2019-08-16 |
Tablets (1) · secukinumab (1)
Germany (2)
2016 (1)